Core Viewpoint - Heron Therapeutics' APONVIE® has been included in the Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV), highlighting its significance in preventing PONV in surgical patients [1][2][3]. Group 1: PONV Guidelines and APONVIE - PONV affects approximately 30% of general surgical patients and up to 80% of high-risk patients, making it a major cause of dissatisfaction post-surgery [2]. - APONVIE is recognized as an NK-1 receptor antagonist for PONV prevention, noted for its long half-life and rapid 30-second IV administration, which allows for quicker onset compared to oral formulations [2][6]. - The guidelines indicate that aprepitant, either alone or in combination therapies, significantly reduces the risk of PONV and is comparable or superior to ondansetron for prophylaxis [2][6]. Group 2: Importance of PONV Management - The release of the PONV Guidelines is timely as more surgeries are performed in outpatient settings, emphasizing the need for effective PONV management to ensure safe recoveries [3]. - The guidelines recommend a multimodal approach for high-risk patients, suggesting the use of three or more agents for prophylaxis [3][4]. - There is a focus on the importance of long-acting antiemetics to extend protection against nausea and vomiting beyond the hospital setting, addressing the risks of post-discharge nausea and vomiting (PDNV) [4][6]. Group 3: Company Overview - Heron Therapeutics is a commercial-stage biotechnology company dedicated to improving patient care through innovative therapeutic solutions [8]. - APONVIE, approved by the FDA in September 2022 and commercially available since March 2023, is positioned as a key product in the company's portfolio aimed at enhancing postoperative recovery experiences [7][8].

Core Viewpoint - Heron Therapeutics has entered into a settlement agreement with Mylan Pharmaceuticals to resolve patent litigations, allowing Mylan to market generic versions of CINVANTI® and APONVIE® starting June 1, 2032, or earlier under certain conditions [1][2]. Group 1: Settlement Agreement Details - The settlement resolves ongoing patent litigations initiated by Heron in September 2023 and January 2024 against Mylan's applications for generic versions of CINVANTI® and APONVIE® [2]. - Mylan will receive a license under the Heron Patents to market the generic drugs in the U.S. [1][2]. Group 2: Company Background - Heron Therapeutics is a commercial-stage biotechnology company focused on developing therapeutic innovations to improve patient care, particularly in acute care and oncology [3]. - The company utilizes advanced science and patented technologies to create and commercialize a portfolio of products aimed at enhancing the standard of care [3].